+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function



Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function



Oncotarget 7(33): 53820-53836



This study was designed to identify novel microRNAs (miRNAs) in plasma for detecting and monitoring hepatocellular carcinoma (HCC), independent of hepatic function and background liver diseases with different etiologies. (1) Four oncogenic miRNAs (miR-151, 155, 191 and 224) with high expression in HCC tissues were selected as candidates. (2) Quantitative RT-PCR using plasma samples from 107 HCC patients and 75 healthy volunteers revealed a significantly higher level of plasma miR-224 in HCC patients than in healthy volunteers according to a small-scale analysis (P < 0.0001), two independent large-scale cohort analysis (P < 0.0001, AUC 0.908). (3) miR-224 expression was significantly higher in HCC tissues and HCC cell lines than in normal hepatic tissues and fibroblasts, respectively. (P = 0.0011, 0.0150) (4) Plasma miR-224 reflected tumor dynamics; preoperative plasma levels of miR-224 were significantly reduced in postoperative samples (P = 0.0058), and plasma miR-224 levels were significantly correlated with paired miR-224 levels in HCC tissues (P = 0.0005). (5) Furthermore, plasma miR-224 levels significantly discriminated HCC patients from patients with chronic liver disease (P = 0.0008). A high plasma miR-224 level was significantly correlated with larger tumor size (P = 0.0005) and recurrences (P = 0.0027). The plasma miR-224 level could accurately detect small tumors less than 18 mm preoperatively. We performed a systematic review of the NCBI database and selected candidate miRNAs reported as highly expressed in HCC tissue. Plasma miR-224 may be a sensitive biomarker for screening HCC and monitoring tumor dynamics.

(PDF emailed within 1 workday: $29.90)

Accession: 057409958

Download citation: RISBibTeXText

PMID: 27462777


Related references

The heterogeneity of plasma miRNA profiles in hepatocellular carcinoma patients and the exploration of diagnostic circulating miRNAs for hepatocellular carcinoma. Plos One 14(2): E0211581, 2019

Plasma microRNA profiles: identification of miR-23a as a novel biomarker for chemoresistance in esophageal squamous cell carcinoma. Oncotarget 7(38): 62034-62048, 2016

Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Journal of Hepatology 56(1): 167-175, 2012

Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma. Hepatology Research 2019, 2019

Factors influencing circulating MicroRNA level in the studies of hepatocellular carcinoma biomarker. Neoplasma 62(5): 798-804, 2015

Exploration of genome-wide circulating microRNA in hepatocellular carcinoma: MiR-483-5p as a potential biomarker. Cancer Epidemiology, Biomarkers and Prevention 22(12): 2364-2373, 2014

Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncology Letters 6(6): 1811-1815, 2013

MicroRNA expression profiles of circulating microvesicles in hepatocellular carcinoma. Acta Gastro-Enterologica Belgica 76(4): 386-392, 2014

microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Digestive Diseases and Sciences 59(6): 1099-1107, 2014

Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Oncotargets and Therapy 6: 577-583, 2013

Circulating microRNA-200 Family as Diagnostic Marker in Hepatocellular Carcinoma. Plos One 10(10): E0140066, 2016

Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. Liver International 37(6): 888-896, 2017

Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening. Tumour Biology 36(9): 7167-7174, 2016

Identification of Circulating Biomarker Candidates for Hepatocellular Carcinoma (HCC): An Integrated Prioritization Approach. Plos One 10(9): E0138913, 2016

Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. Ebiomedicine 30: 138-147, 2018